Targeting of drugs and nanoparticles to tumors

By Erkki Ruoslahti, Sangeeta N. Bhatia, Michael J. Sailor. Journal of Cell Biology, 2010

859 citations recorded by the source corpus.

The various types of cells that comprise the tumor mass all carry molecular markers that are not expressed or are expressed at much lower levels in normal cells. These differentially expressed molecules can be used as docking sites to concentrate drug conjugates and nanoparticles at tumors. Specific markers in tumor vessels are particularly well suited for targeting because molecules at the surface of blood vessels are readily accessible to circulating compounds. The increased concentration of a drug in the site of disease made possible by targeted delivery can be used to increase efficacy, reduce side effects, or achieve some of both. We review the recent advances in this delivery approach with a focus on the use of molecular markers of tumor vasculature as the primary target and nanoparticles as the delivery vehicle.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/966a742faf5e40acc209e5ac29c03c5b34404aa6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Molecular Biology

Citations in the corpus

Delivering nanomedicine to solid tumors (2010, background): “Nanoparticles with targeting ligands (for example, monoclonal antibodies, their Fab fragments and other moieties) on their surface have been developed to specifically recognize and bind to the tumor vasculature or cancer cells”
Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. (2011, background): “The consequences of such effects in nanoparticle therapies based on explicit cancer cell targeting or the leaky vasculature of tumours (enhanced permeability effect”
Hallmarks of cancer: the next generation. (2011, neutral): “Other avenues of research are revealing distinctive gene expression profiles of tumor-associated endothelial cells and identifying cell-surface markers displayed on the lumenal surfaces of normal versus tumor endothelial cells (Nagy et al., 2010; Ruoslahti et al., 2010; Ruoslahti, 2002).”
Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers (2012, neutral): “From a drug delivery point of view, targeting of cancer is the most pursued area, with emphasis on delivery of chemotherapeutics and radiotherapeutics.(7,8) However, increasing applications of SPIONs have also been found in the areas of gene delivery, cell death with the help of local hyperthermia, ”